It was previously thought that individuals who had diabetes and developed progressive diabetic nephropathy (DN) and/or ESRD were simply exposed to long durations of diabetes with relatively poor glycemic control. In other words, all individuals with diabetes were assumed to be at essentially equivalent risk for developing nephropathy, allowing for differences in their ambient serum glucose concentration. In support of the concept that exposure to a hyperglycemic environment led to DN (often with coexisting obesity, metabolic syndrome, hypertension, and hyperlipidemia), clinical trials have conclusively demonstrated that improving glycemic control delays and, in some cases, may prevent the subsequent development of albuminuria, DN, and macrovascular complications such as coronary artery disease (1,2). The concept that select individuals with diabetes were at differential risk for developing nephropathy on the basis of familial aggregation of kidney disease was initially reported in 1989 but has only recently gained broad acceptance among nephrologists and diabetologists (3).
Familial Aggregation of DN
The notion that genetic factors contribute to any complex disease rests on the demonstration of familial aggregation. Familial clustering of nephropathy could result from shared genes, environmental exposures, or their combination.
After repeated demonstrations that DN and diabetic ESRD aggregated in families (4) and that this observation was consistent in all ethnic groups evaluated and was to a large extent independent of blood glucose concentration, the issue of coincident familial clustering of an unrecognized environmental risk factor or a lack of access to adequate health care arose. Despite multiple confirmations of familial aggregation of DN and diabetic ESRD, there was concern that recruitment of biased samples could have occurred in the predominantly single-center reports. Familial aggregation of DN has since been demonstrated to be independent from family size, the number of relatives affected with diabetes and hypertension, socioeconomic status, and inadequate access to health care (5), strongly suggesting the existence of DN-susceptibility genes.
In the largest analysis to date, nearly 26,000 incident US dialysis patients from more than 450 dialysis clinics were screened for family history of ESRD (6). Individuals with known genetic disorders (e.g., autosomal dominant polycystic kidney disease, hereditary nephritis) and urologic disorders (surgical nephrectomy) were excluded. Independent risk factors for a family history of ESRD in first- or second-degree relatives included earlier age at ESRD onset, female gender, black ethnicity, and diabetes-associated nephropathy. Nearly 32% of black women and 27% of black men reported having close relatives with ESRD, compared with 15 and 12% of European Americans, respectively. These data were collected from a wide geographic area that contained a range of dialysis facility types (academic, large chain, independent, for profit, and nonprofit), and questionnaires were completed by the local nursing and social worker staffs. This large study confirmed the results of the single-center reports. An even larger percentage of individuals with ESRD likely have relatives who either have clinically silent nephropathy that has not yet progressed to need for dialysis or died from cardiovascular causes related to chronic kidney disease before starting dialysis (7). A recent US population-based sample (8) detected association between serum levels of C-reactive protein and family history of ESRD while confirming the effects of ethnicity, gender, and cause of renal disease.
Urinary albumin excretion is a hallmark of DN; however, albuminuria can fluctuate widely, even fully resolve, and is a stronger predictor of cardiovascular disease (CVD) events than progressive nephropathy. Heritability estimates for albuminuria (urine albumin:creatinine ratio) and kidney function (GFR) allow for the estimation of genetic and environmental contributions to DN. A heritability (h2) = 1 suggests the presence of a Mendelian disorder (e.g., autosomal dominant polycystic kidney disease), whereas h2 = 0 reveals the contribution of environmental factors. Heritability estimates for albuminuria were significant, ranging from 0.3 to 0.44 in Finnish (9), New England (10), and southeastern US (11) families enriched for members with type 2 diabetes, and the estimate was higher (h2 = 0.49) in Hypertension Genetic Epidemiology Network (HyperGEN) families enriched for multiple siblings with hypertension (12). Similarly, GFR was significantly heritable in families with diabetes and hypertension, ranging from 0.36 to 0.75 (11,13,14). These results are impressive, considering that albuminuria and GFR change during the course of DN. Thus, familial aggregation of these intermediate phenotypes solidifies the concept that DN susceptibility genes exist. Environmental factors seemed to be minor contributors to these relatively high h2 estimates. Two segregation analyses in multiplex families with members who had type 2 diabetes suggested that major gene effects likely contribute to the development of DN (15,16). Quinn et al. (17) reported that an autosomal dominant major gene with a common disease allele was likely present.
In addition, familial aggregation of renal histology is observed in siblings with diabetes, independent of diabetes duration and disease control (18); a greater prevalence of hypertensive parents among children with diabetes and nephropathy are seen (19); and ethnic differences in susceptibility to DN exist (20). Together, these observations support genetic contributions to DN. These epidemiologic studies set the stage for genome-wide searches to detect chromosomal regions that harbor DN-susceptibility genes.
Genetic Approaches to Identifying DN Genes
In tandem with advances in the epidemiology of DN, options for gene identification in common complex diseases have rapidly evolved with completion of the Human Genome Project and an improved understanding of the haplotype block structure of our genome. Broad categories of molecular genetic approaches include linkage and association studies, with recent advances in association analysis including mapping by admixture disequilibrium (MALD) (21) and whole-genome association (WGA) studies (22).
Linkage studies are family based and evaluate coincident inheritance of polymorphic genetic markers that are relatively uniformly distributed throughout the genome with the presence or absence of disease among relatives. In DN, families have often been limited to sibling pairs or two-generation families because of the late age at onset of DN. Initial linkage studies were performed using microsatellite repeat genetic markers; however, single-nucleotide polymorphisms (SNP) are now commonly used with equal or better information content at lower cost. Because we receive one copy or allele of a given gene (or a given polymorphic genetic marker) from each parent, among full siblings, 50% are expected to share one (of two) alleles at a given locus, 25% share both alleles, and 25% share neither allele; overall allele sharing is at 50%. In siblings who are concordant for DN (affected sibling pairs) and are tested for sharing of a polymorphic marker that is in linkage disequilibrium with a nearby DN locus, analysis of large numbers of sibling pairs would demonstrate that significantly more than 50% of affected sibling pairs share the linked genetic marker. In contrast, siblings who are discordant for DN (discordant sibling pairs) are expected to demonstrate significantly less than 50% sharing of the polymorphic marker that is linked to the nearby DN disease locus. Chromosomal regions linked with DN in families (e.g., linkage peaks) presumably contain DN susceptibility gene(s) or are false-positive results. Genome-wide linkage analyses provide a model-free screen of the entire genome; however, linkage is generally regarded as less sensitive compared with association analyses (see below, Table 2) but does have the capability of identifying genomic regions that harbor multiple genes or multiple variants with small effect sizes, in addition to the simpler scenario of a single strong contributor to risk.
Because of the need to recruit large numbers of informative families, linkage studies are difficult, expensive, and time-consuming. Association analyses using unrelated case patients and control subjects are simpler and often far less expensive. Association analysis approaches are used for detecting disease genes (or markers that are in linkage disequilibrium with causative genes) but may be subject to false-positive results because of population stratification. The important capability of association analyses is the ability to detect relatively modest effect sizes (e.g., good power to detect odds ratios (OR) of 1.3 to 1.5 or less in 500 case patients and 500 control subjects). It should be noted that even with this approach, success depends on the existence of a relatively common risk allele. Family-based association studies, also called family-based transmission disequilibrium testing (TDT), tend to reduce the potential bias of population stratification. Recently, it has become possible to perform association analyses in large numbers of case patients with DN and control subjects with diabetes and without nephropathy using 500,000 (or more) SNP markers spaced across all chromosomes, a WGA analysis. This approach will become even more powerful in the near future with technologies using upward of 1 million SNP markers for association analysis. WGA remains an expensive undertaking, but several groups have DN studies planned or under way.
Ethnic differences in disease course, such as occur in DN, can suggest the presence of causative genetic factors. Genetic admixture between two populations results from the sharing of alleles that were initially far more common in one ethnic group. For example, black and European American admixture has resulted in approximately 20% admixture of “European alleles” in the black population. A novel technique to detect association, MALD, tests for association of ethnic-specific genetic markers that were more common in one ethnic group (either the one with the higher or the lower disease prevalence) and are then disproportionately transmitted into affected members in the other ethnic group (21). MALD is potentially useful in situations in which ethnic differences in disease incidence exist between recently admixed populations. Examples of each of these techniques as applied to DN are described next.
Genome-Wide Linkage Scans for DN
Six complete genome-wide linkage scans have been published in type 2 DN, with one in type 1 DN (and another partial genome scan in type 1 DN) (14,23–29). Although most of these analyses evaluated small numbers of families from different ethnic groups, several consistent regions of linkage have been detected (Table 1). In type 1 DN, two reports identified linkage to markers on chromosome 3q in white families (27,28), and this location was subsequently replicated in a family-based TDT analysis (30). A 3q peak was also observed in a type 2 DN genome scan in black families (23), in the same region but distal to the white peak. Several regions of linkage have been replicated among the various groups with type 2 DN, as well. The 18q22–23 linkage region was replicated in four populations (23,26,29), the 7q35–36 peak in three reports (25,26,31), and the 7p15 and 10q26 peaks in two each (14,23,32). Positional candidate genes for DN in these regions are now being sought and identified (Table 2).
Chromosome 3q Linkage Peak in Type 1 DN
Intensive efforts have been undertaken to identify the causative gene under the 3q linkage peak in type 1 DN. The nearby angiotensin II type 1 receptor gene was quickly excluded from involvement (27). Vionnet et al. (33) subsequently evaluated 14 candidate genes for type 1 DN on chromosome 3q in an association analysis using a combined population of 1057 unrelated Danish, Finnish, and French case patients with type 1 DN, 1127 control subjects with diabetes and without nephropathy, and 532 trio families. In an initial association analysis, polymorphisms in three genes—glucose transporter 2, kininogen, and adiponectin—were nominally associated with DN. Attempts at replication using TDT testing in trios confirmed significant association in the adiponectin gene (ADIPOQ) with excess transmission of the A allele in the promoter to individuals with DN and of the G allele to those without DN (P = 0.011). This suggests that polymorphisms in ADIPOQ may be involved in DN susceptibility. The pooled odd ratio for the ADIPOQ_Prom 2GA allele was 1.46 (95% confidence interval 1.11 to 1.93; P = 0.006), with results driven predominantly from the Danish (P = 0.011) and French (P = 0.071) cohorts.
Adiponectin is an adipocytokine that is produced by fat cells (34). Circulating levels of adiponectin are reduced in individuals who are obese and have diabetes, and levels rise after weight loss. Positive correlations have been reported between circulating high molecular weight adiponectin level and HDL cholesterol, with negative correlations among circulating inflammatory markers, triglycerides, and homeostasis model assessment of insulin resistance. Adiponectin gene polymorphisms reportedly play a protective role in susceptibility to coronary heart disease (35). It is thought to have antiatherogenic properties via downregulation of expression of adhesion molecules on endothelial cells through inhibition of NF-κB activation, reduction of endothelial oxidative stress and proliferation while stimulating nitric oxide synthase activity, and reduction of vascular smooth muscle cell proliferation by inhibiting the effects of a number of growth factors (34). With clear relationships between atherosclerosis and DN, adiponectin is likely a gene that may play a role in both vascular processes.
TDT and Microsatellite Association Analysis in Type 1 DN
Ewens et al. (30) tested 115 candidate genes for association with type 1 DN using TDT. This was a comprehensive analysis of a large number of potential candidate genes that previously were implicated in the pathogenesis of DN. The power of this study was limited by the inclusion of only 72 trio families. Several genes were nominally associated with type 1 DN, including genes in the broad categories of extracellular matrix material (COL4A1, LAMA4, and LAMC1), matrix metabolism (TIMP3 and MMP9), transcription factors/signaling molecules (HNF1B1/TCF2, NRP1, PRKCB1, SMAD3, and USF1), growth factors/growth factor receptors (IGF1, TGFBR2, and TGFBR3), and those that are believed to be important in the regulation of kidney function (AGTR1, AQP1, BCL2, CAT, GPX1, LPL, and p22phox).
McKnight et al. (36) performed a novel genome-wide fluorescence-based DNA microsatellite association screen in 400 Irish individuals with diabetes (200 case patients with type 1 DN and 200 control subjects without nephropathy). This “low-resolution” WGA study used 6000 microsatellite markers and pooled DNA samples from case patients and control subjects. The top 50 most consistently associated marker pools were identified, and the samples that composed the pools were individually genotyped. Two markers on chromosome 10q (D10S558 and D10S1435) were significantly associated with type 1 DN, and four additional markers demonstrated trends toward association (D6S281, D4S293, D2S291, and D17S515). Of note, the 10q association with D10S1435 was previously observed in nondiabetic ESRD in black individuals (37).
Type 2 DN
To date, six complete genome-wide scans (GWS) have been published in type 2 DN. The largest are the interim and final reports from the National Institute of Diabetes and Digestive and Kidney Diseases–sponsored Family Investigation of Nephropathy and Diabetes (FIND) (26,38,39). Although these GWS were performed in different ethnic groups, most contained small numbers of families, and each used variable definitions for DN; common linkage peaks on 18q22–23, 7q35–36, 7p15, and 10q26 were detected across reports. This replication strongly suggests that causative type 2 DN genes underlie each peak and reduces the likelihood that they are false-positive results. We describe the linkage reports next, followed by association analyses that evaluated potentially causative candidate genes underlying linkage peaks.
Chromosome 18q.22–23: The Carnosinase 1 Gene
The chromosome 18q22–23 linkage peak in type 2 DN demonstrated a logarithm of odds score >6 (roughly corresponding to P < 10−6) in 18 large Turkish families who lived in Germany (29). Although not identified in an initial GWS in Pima Indians, markers in the 18q region were found to be linked in this population as well. Subsequently, the 18q linkage was confirmed in black sibling pairs with diabetic ESRD and in members of the National Institute of Diabetes and Digestive and Kidney Diseases–supported FIND in the first-phase GWS, which contained 1227 individuals in 378 families (linkage in the FIND was predominantly driven by the European American and American Indian families). This consistent evidence for linkage strongly supported the existence of a type 2 DN gene(s) in this region (23,26).
Using association analysis to follow up the linkage peak, ZNF236, a glucose-regulated Kruppel-like zinc finger gene on 18q22-q23, was rapidly excluded from involvement (40). Janssen et al. (41) next reported that the carnosinase 1 gene (CNDP1) was associated with type 2 DN in an analysis of 135 case patients with DN and 107 control subjects with diabetes and without nephropathy from >5000 screened medical charts. Participants were unrelated white individuals who lived in the Czech Republic, Netherlands, Germany, and Qatar. Of 18 variants tested in CNDP1, the D18S880 polymorphism was associated with type 2 DN in a subset of these individuals. The number of leucine residues coded for by numbers of CTG repeats was the associated variant, with individuals homozygous for the 5 leucine–5 leucine (5L-5L) variant protected from the development of DN in an autosomal recessive manner. Overall, 43% (46 of 107) of control subjects were 5L-5L homozygotes, compared with 27% (37 of 135) of case patients (OR 2.56; P = 0.0028); some of these participants had type 1 DN. In associated studies, serum carnosinase concentrations were lowest among 5L-5L homozygotes; the addition of carnosine to podocyte cell lines that were exposed to high concentrations of glucose reduced production of fibronectin and type VI collagen; exposing mesangial cell lines to a hyperglycemic milieu and 20 mmol/L L-carnosine reduced TGF-β production; and the kidneys of humans with DN revealed enhanced staining for CNDP1. Although this small study replicated results in three individual sets of case patients and control subjects, further replication was provided in a larger and less selective analysis of 294 European Americans with type 2 DN–associated ESRD, 258 patients with type 2 diabetes and without nephropathy, and 306 healthy control subjects (42). Similar to the report by Janssen et al. (41), 38.6% of healthy subjects, 36.8% of patients with type 2 diabetes and without nephropathy, and 26.1% of patients with definite DN were 5L-5L homozygotes (OR for definite DN versus type 2 diabetes without nephropathy 1.65; P = 0.02). Yard (43) developed reporter assays for the five, six, and seven leucine CNDP1 variants that were expressed in Cos-7 cells and determined the amount of secreted protein. The five leucine-expressing Cos-7 cells secreted significantly less carnosinase than the others, demonstrating that the hydrophobic leucine stretch is of critical importance for targeting this protein into the secretory pathway. Taken together, these studies strongly support a role for the carnosinase gene CNDP1 in susceptibility to type 2 DN. Carnosine is a scavenger of oxygen free radicals, inhibits formation of advanced glycosylation end products, and inhibits TGF-β production (44). Individuals who are CNDP1 5L-5L homozygotes secrete less carnosinase and are therefore expected to have higher carnosine levels with protection from DN. The role of CNDP1 in DN among black individuals is less clear: There is no evidence of 5L protection; however, other CNDP1 alleles may influence risk (45).
Chromosome 7p14: The Engulfment and Cell Motility 1 and IGF-Binding Protein 1 Genes
Shimazaki et al. (46) performed a gene-centric WGA in unrelated Japanese individuals who had type 2 DN and diabetes without nephropathy. A SNP in the 18th intron of engulfment and cell motility 1 (ELMO1) on chromosome 7p14 was strongly associated with DN, and the region of association extended 100 kb upstream and downstream from this SNP. The 7p region was also linked with susceptibility to type 2 diabetes in 638 black affected sibling pairs from 247 multiplex families who had type 2 diabetes and each had a proband with advanced DN (47), in a subset of 266 affected sibling pairs who were concordant for diabetic ESRD from 166 of these families (23) and in FIND families (26).
Because ELMO1 is a large gene, Shimazaki et al. (46) genotyped an additional 516 polymorphisms in 640 Japanese DN case patients and 426 control subjects. Several of these additional markers were also associated, the strongest being the + 9170 A/G SNP (GG versus AG + AA; OR 2.67; P = 0.000008). In situ hybridization revealed increased gene expression of ELMO1 in diabetic mouse kidney tissue; increased expression of ELMO1 was seen in COS cell lines that were exposed to a hyperglycemic environment, and these cells overexpressed extracellular matrix protein genes (collagen type 1 and fibronectin) and underexpressed matrix metalloproteinase genes. Our analyses confirm a role for this gene in susceptibility to both diabetes and ESRD in black individuals (48), although a single report in white individuals failed to replicate this association (49).
Previously, ELMO1 was known to play a role in phagocytosis of dying cells and is required for cell migration and changes in cell shape. Maeda's group (50) in Japan subsequently demonstrated that ELMO1 expression was increased in an animal model of chronic glomerulonephritis, resulting in overexpression of extracellular matrix proteins and loss of cell adhesive properties; hence, ELMO1 could plausibly play a role in the development of several glomerular disorders, including DN.
Another positional candidate gene on 7p14 that has been implicated in susceptibility to type 2 DN is IGF-binding protein 1 (IGFBP1). Stephens et al. (51) evaluated 732 patients with type 2 diabetes in the Salford Diabetes Register. Nearly 25% of the male and 12% of the female participants had DN. Several polymorphic SNP were associated with a reduced prevalence of nephropathy, and haplotype analysis revealed that 97% of the genetic variation for IGFBP1 in the population sample could be accounted for using two “renoprotective” SNP. One of these SNP may affect the tissue delivery of IGF-1 by IGFBP1, because this SNP is in exon 4 near the integrin-binding RGD motif. The RGD motif is believed to be important in extracellular matrix interactions mediated by the binding of integrin-α5β1. It is possible that both of these genes on 7p are involved in susceptibility to type 2 DN.
Chromosome 7q35: Endothelial Nitric Oxide Synthase
Endothelial nitric oxide synthase (NOS3) is a positional and functional candidate gene for DN that is located on chromosome 7q. NOS3 regulates systemic endothelial function by maintaining endothelial-dependent vasodilation, including in the renal microcirculation. NO is synthesized from l-arginine by NOS. In rodent models, long-term NO blockade leads to elevated glomerular capillary pressure with proteinuria and glomerulosclerosis (52). The T-786C polymorphism is known to reduce NOS3 gene promoter activity and has been associated with coronary artery disease and DN (53). It is possible that the NOS3 association is with albuminuria, in and of itself a potent CVD risk factor, relative to risk for development of progressive DN (54–58).
Additional Candidate Genes of Interest
In addition to the genes described in the previous sections, a wide range of biologically relevant genes have been assessed for association with DN. A summary of salient observations is provided in Table 2. For obvious reasons, there has been longstanding interest in whether genes in the renin-aldosterone-angiotensin axis were involved in propensity toward renal failure or whether gene polymorphisms could provide useful markers to predict medical response to therapy (pharmacogenomics). Unfortunately, many such studies were performed with inadequate interrogation of the genes (e.g., too few SNP evaluated) and contained small numbers of cases and controls. The angiotensin-converting enzyme gene (ACE) on chromosome 17q23 has repeatedly been evaluated for a role in DN. Polymorphisms in this gene are clearly associated with circulating ACE levels (59), and reports suggested association between the ACE DD allele and type 1 DN (60–62). Although a large meta-analysis failed to confirm the DN association in white individuals (63), a recent report (64) from the European Rational Approach for the Genetics of Diabetic Complications (EURAGEDIC) Study Group detected evidence for association of several ACE polymorphisms (including the “D” deletion allele) in a large case-control study, with somewhat consistent findings in a family-based TDT analysis. The results were strongest among the French cohort and clearly weaker in the Finnish sample, suggesting heterogeneous effects among different ethnic groups. In addition, Ng et al. (65) evaluated three tagging markers (A-5466C, T-3892C, and Ins/Del) at the ACE locus for disease association with type 2 DN. Although none of these markers was associated with DN in isolation, haplotype analysis revealed that nearly twice as many of the DN cases (13.6%) inherited the A-5466C, T-3892C, Deletion (ATD) “risk” haplotype, compared with diabetes non-nephropathy controls (7.5%; P = 0.009). This report further suggested that haplotypes at the ACE locus may be associated with DN.
Manganese superoxide dismutase (MnSOD or SOD2) on 6q25 has been implicated in risk for type 2 DN on the basis of the role of oxidative stress on renal cell injury. A valine/alanine polymorphism in the targeting sequence of the SOD2 gene (rs4880) seems to affect the efficiency with which MnSOD is transported across the mitochondrial matrix. Association of the Val/Val genotype of SOD2 with type 2 DN was initially reported in Korean (66) and Japanese (67) cohorts. This genotype was then associated with type 1 DN in European cigarette smokers, in whom inheritance of the Val/Val genotype was associated with a significant 32% increase in overall risk for DN (68). In the highest risk group of smokers who inherited the Val/Val genotype, the risk for DN was >2.5 times greater than in the low-risk group. In vitro studies demonstrate that the valine polymorphism (relative to alanine) results in less efficient transport of SOD, potentially compromising the ability of the cell to neutralize superoxide radicals and placing susceptible individuals at risk for oxidative stress, albuminuria, and resulting mesangial expansion and glomerulosclerosis.
The apolipoprotein E gene (APOE) on chromosome 19q has also been associated with susceptibility to type 1 DN (69) and type 2 DN (70). ApoE is a polymorphic protein that consists of three isoforms, E2, E3, and E4, encoded by the alleles ε2, ε3, and ε4, which are defined by a single amino acid substitution at two sites (reviewed by Mahley and Rall [71]). These substitutions have been shown to alter the affinity of ApoE for its receptors, thereby influencing lipid metabolism. The ε4 allele has previously been associated with increased risk for both Alzheimer's disease and CVD. A number of studies have investigated associations between the ApoE isoforms and DN; however, the results remain inconclusive. This may be due in part to the small sample size used in all but one study (70). Several studies (72–74) concluded that the ApoE4 isoform is associated with protection from type 2 DN in both white and Japanese individuals. Hsu et al. (70) corroborated this finding, demonstrating that the frequency of the ε4 allele is decreased in type 2 diabetes and chronic kidney disease and revealing association between the ε2 allele and chronic kidney disease, a result that is consistent with several older studies of type 1 DN in white individuals (75,76) and one of type 2 DN in Japanese individuals (77). In contrast, an equal number of studies (78–80) failed to find any association between ε2 and type 2 DN or microvascular complications associated with type 2 diabetes. Given the significance of ApoE in lipid metabolism, the mechanism behind associations between ApoE polymorphisms and DN is likely to be complex.
Conclusions
There is now a consensus that genes contribute to risk for DN. Earlier investigations that focused on genetic mapping and analysis of specific candidate genes provided the foundation for current studies that target linkage peaks and specific genes. As our knowledge of DN (and other complex disorders) increases, the sophistication of approaches and size and cost of these studies have also increased. These efforts are beginning to identify genes that have increasingly compelling evidence for association. Recent successes in identifying diabetes and other genes through linkage or WGA methods suggest that we may be at the threshold of an exciting era for understanding the genetic risk factors underlying DN. It is noteworthy that a second report of a DN gene, plasmacytoma variant translocation gene PVT1, identified using a WGA approach, has appeared (81).
There are still challenging issues in this area of research. Emerging evidence suggests that patients with type 2 diabetes likely have differing causes of disease and that different ethnic groups may have variable risk associated with a specific gene. If this proves to be true, then efforts in minority populations will need to be increased. Finally, the importance of finding DN genes is profound. Identification of risk genes could provide a powerful tool for identifying the subset of patients who have diabetes and will progress to nephropathy and ESRD. Early identification will facilitate earlier intervention, ultimately delaying and reducing the impact of DN.
Disclosures
None.
;)
Table 1: Summary of results from genome-wide linkage scans for diabetic nephropathya
Table 2: Candidate genes for DN
Published online ahead of print. Publication date available at www.cjasn.org.
References
1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS Group: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int63 :225– 232,2003
2. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group. N Engl J Med342 :381– 389,2000
3. Seaquist ER, Goetz FC, Rich SS, Barboso J: Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med320 :1161– 1165,1989
4. Satko SG, Sedor JR, Iyengar SK, Freedman BI: Familial clustering of chronic kidney disease. Semin Dial20 :229– 236,2007
5. Lei HH, Perneger TV, Klag MJ, Whelton PK, Coresh J: Familial aggregation of renal disease in a population-based case-control study. J Am Soc Nephrol9 :1270– 1276,1998
6. Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, McClellan WM: Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol25 :529– 535,2005
7. Satko SG, Langefeld CD, Daeihagh PD, Bowden DW, Rich SS, Freedman BI: Nephropathy in siblings of African-Americans with overt type 2 diabetic nephropathy. Am J Kidney Dis40 :489– 494,2002
8. McClellan W, Speckman R, McClure L, Howard V, Campbell RC, Cushman M, Audhya P, Howard G, Warnock DG: Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Renal Cohort Study. J Am Soc Nephrol18 :1344– 1352,2007
9. Forsblom CM, Kanninen T, Lehtovirta M, Saloranta C, Groop LC: Heritability of albumin excretion rate in families of patients with type II diabetes. Diabetologia42 :1359– 1366,1999
10. Fogarty DG, Rich SS, Hanna LS, Warram JH, Krolewski AS: Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int57 :250– 257,2000
11. Langefeld CD, Beck SR, Bowden DW, Rich SS, Wagenknecht LE, Freedman BI: Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis5 :796– 800,2004
12. Freedman BI, Beck SR, Rich SS, Heiss G, Lewis CE, Turner S, Province MA, Schwander KL, Arnett DK, Mellen BG: A genome-wide scan for urinary albumin excretion in hypertensive families. Hypertension42 :291– 296,2003
13. Bochud M, Elston RC, Maillard M, Bovet P, Schild L, Shamlaye C, Burnier M: Heritability of renal function in hypertensive families of African descent in the Seychelles (Indian Ocean). Kidney Int67 :61– 69,2005
14. Placha G, Poznik GD, Dunn J, Smiles A, Krolewski B, Glew T, Puppala S, Schneider J, Rogus JJ, Rich SS, Duggirala R, Warram JH, Krolewski AS: A genome-wide linkage scan for genes controlling variation in renal function estimated by serum cystatin C levels in extended families with type 2 diabetes. Diabetes55 :3358– 3365,2006
15. Imperatore G, Knowler WC, Pettitt DJ, Kobes S, Bennett PH, Hanson RL: Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes49 :1049– 1056,2000
16. Fogarty D, Hanna LS, Wantman M, Warram JH, Krolewski AS, Rich SS: Segregation analysis of urinary albumin excretion in families with type 2 diabetes. Diabetes49 :1057– 1063,2000
17. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia39 :940– 945,1996
18. Fioretto P, Steffes MW, Barboso J, Rich SS, Miller ME, Mauer M: Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes48 :865– 869,1999
19. Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson-Fernholm KJ, Gronhagen-Riska C, Parving HH, Groop PH: Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes47 :439– 444,1998
20. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV: Ethnic disparities in diabetic complications in an insured population. JAMA287 :2519– 2527,2002
21. Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD, Malasky MJ, Scafe C, Le E, De Jager PL, Mignault AA, Yi Z, De The G, Essex M, Sankale JL, Moore JH, Poku K, Phair JP, Goedert JJ, Vlahov D, Williams SM, Tishkoff SA, Winkler CA, De La Vega FM, Woodage T, Sninsky JJ, Hafler DA, Altshuler D, Gilbert DA, O'Brien SJ, Reich D: A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet74 :1001– 1013,2004
22. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science316 :1341– 1345,2007
23. Bowden DW, Colicigno CJ, Langefeld CD, Sale MM, Williams A, Anderson PJ, Rich SS, Freedman BI: A genome scan for diabetic nephropathy in African Americans. Kidney Int66 :1517– 1526,2004
24. Chen G, Adeyemo AA, Zhou J, Chen Y, Doumatey A, Lashley K, Huang H, Amoah A, Agyenim-Boateng K, Eghan BA, Okafor G, Acheampong J, Oli J, Fasanmade O, Johnson T, Rotimi C: A genome-wide search for linkage to renal function phenotypes in West Africans with type 2 diabetes. Am J Kidney Dis49 :394– 400,2007
25. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC: Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes47 :821– 830,1998
26. Iyengar SK, Abboud HE, Goddard KA, Saad MF, Adler SG, Arar NH, Bowden DW, Duggirala R, Elston RC, Hanson RL, Ipp E, Kao WH, Kimmel PL, Klag MJ, Knowler WC, Meoni LA, Nelson RG, Nicholas SB, Pahl MV, Parekh RS, Quade SR, Rich SS, Rotter JI, Scavini M, Schelling JR, Sedor JR, Sehgal AR, Shah VO, Smith MW, Taylor KD, Winkler CA, Zager PG, Freedman BI: Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: The Family Investigation of Nephropathy and Diabetes (FIND). Diabetes56 :1577– 1585,2007
27. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS: Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: Results of novel discordant sib-pair analysis. Diabetes47 :1164– 1169,1998
28. Osterholm AM, He B, Pitkaniemi J, Albinsson L, Berg T, Sarti C, Tuomilehto J, Tryggvason K: Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. Kidney Int71 :140– 145,2007
29. Vardarli I, Baier L, Hanson RL, Akkoyum I, Fischer C, Rohmeiss P, Basci A, Bartram C, Van Der Woude F, Janssen JA: Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3–23. Kidney Int62 :2176– 2183,2002
30. Ewens KG, George RA, Sharma K, Ziyadeh FN, Spielman RS: Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes54 :3305– 3318,2005
31. Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, Smiles A, Krolewski B, Fogarty DG, Moczulski D, Araki S, Makita Y, Ng DP, Rogus J, Duggirala R, Rich SS, Warram JH: A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int69 :129– 136,2006
32. Freedman BI, Bowden DW, Rich SS, Valis CJ, Sale MM, Hicks PJ, Langefeld CD: A genome scan for all-cause end-stage renal disease in African Americans. Nephrol Dial Transplant20 :712– 718,2005
33. Vionnet N, Tregouet D, Kazeem G, Gut I, Groop PH, Tarnow L, Parving HH, Hadjadj S, Forsblom C, Farrall M, Gauguier D, Cox R, Matsuda F, Heath S, Thevard A, Rousseau R, Cambien F, Marre M, Lathrop M: Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: Strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes55 :3166– 3174,2006
34. Guzik TJ, Mangalat D, Korbut R: Adipocytokines: Novel link between inflammation and vascular function? J Physiol Pharmacol57 :505– 528,2006
35. Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros CS, Hu FB: Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes55 :1512– 1516,2006
36. McKnight AJ, Maxwell AP, Sawcer S, Compston A, Setakis E, Patterson CC, Brady HR, Savage DA: A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. J Am Soc Nephrol17 :831– 836,2006
37. Freedman BI, Rich SS, Yu H, Roh BH, Bowden DW: Linkage heterogeneity of end-stage renal disease on human chromosome 10. Kidney Int62 :770– 774,2002
38. Iyengar SK, Freedman BI, The FIND Consortium: A multi-ethnic genome-wide linkage study for diabetic nephropathy. The Family Investigation of Nephropathy and Diabetes (FIND) Study [Abstract]. J Am Soc Nephrol18 :608A ,2007
39. Sedor JR, Nelson RG, The FIND Consortium: A genome-wide scan for estimated glomerular filtration rate (eGFR): The Family Investigation of Nephropathy and Diabetes (FIND) Study [Abstract]. J Am Soc Nephrol18 :14A ,2007
40. Halama N, Yard-Breedijk A, Vardarli I, Akkoyun I, Yard B, Janssen B, van der Woude FJ: The Kruppel-like zinc-finger gene ZNF236 is alternatively spliced and excluded as susceptibility gene for diabetic nephropathy. Genomics82 :406– 411,2003
41. Janssen B, Hohenadel D, Brinkkoetter P, Peters V, Rind N, Fischer C, Rychlik I, Cerna M, Romzova M, de Heer E, Baelde H, Bakker SJ, Zirie M, Rondeau E, Mathieson P, Saleem MA, Meyer J, Koppel H, Sauerhoefer S, Bertram CR, Nawroth P, Hammes HP, Yard BA, Zschocke J, Van Der Woude F: Carnosine as a protective factor in diabetic nephropathy: Association with a leucine repeat of the carnosinase gene CNDP1. Diabetes54 :2320– 2327,2005
42. Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, McDonough C, Janssen B, Yard BA, van der Woude FJ, Bowden DW: A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant22 :1131– 1135,2007
43. Reidl E, Koeppel H, Brinkkoetter P, Sternik P, Steinbeisser H, Sauerhoefer S, Janssen B, van der Woude FJ, Yard BA: A CTG polymorphism in the CNDP1 gene determines the secretion of serum carnosinase in Cos-7 transfected cells. Diabetes56 :2410– 2413,2007
44. Boldyrev AA: Problems and perspectives in studying the biological role of carnosine. Biochemistry (Mosc)65 :751– 756,2000
45. McDonough CW, Hicks PJ, Freedman BI, Bowden DW: Genetic evaluation of CNDP1 and CNDP2 polymorphisms in diabetic nephropathy [Abstract]. J Am Soc Nephrol18 :607A ,2007
46. Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D, Babazono T, Tanaka Y, Matsuda M, Kawai K, Iiizumi T, Imanishi M, Shinosaki T, Yanagimoto T, Ikeda M, Omachi S, Kashiwagi A, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakajima M, Nakamura Y, Maeda S: Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes54 :1171– 1178,2005
47. Sale MM, Freedman BI, Langefeld CD, Williams AH, Hicks PJ, Colicigno CJ, Beck SR, Brown WM, Rich SS, Bowden DW: A genome-wide scan for type 2 diabetes in African Americans families reveals evidence for a locus on chromosome 6q. Diabetes53 :830– 837,2004
48. Leak TS, Perlegas PS, Smith SG, Hicks PJ, Li L, Langefeld CD, Keene KL, Sale MM, Freedman BI, Bowden DW: Variants in the ELMO1 gene are associated with diabetes and nephropathy in African Americans [Abstract]. J Am Soc Nephrol18 :14A ,2007
49. Ng DP, Choo SG, Chia KS, Krolewski AS: Evaluation of SLC12A3 and ELM01 SNPs for genetic susceptibility to advanced diabetic nephropathy in type 2 diabetes mellitus [Abstract]. J Am Soc Nephrol17 :390A ,2006
50. Shimazaki A, Tanaka Y, Shinosaki T, Ikeda M, Watada H, Hirose T, Kawamori R, Maeda S: ELMO1 increases expression of extracellular matrix proteins and inhibits cell adhesion to ECMs. Kidney Int70 :1769– 1776,2006
51. Stephens RH, McElduff P, Heald AH, New JP, Worthington J, Ollier WE, Gibson JM: Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes54 :3547– 3553,2005
52. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest90 :278– 281,1992
53. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K: T-786-> C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation99 :2864– 2870,1999
54. Suzuki H, Nagase S, Kikuchi S, Wang Y, Koyama A: Association of a missense Glu298Asp mutation of the endothelial nitric oxide synthase gene with end stage renal disease. Clin Chem46 :1858– 1860,2000
55. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS: Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int57 :405– 413,2000
56. Noiri E, Satoh H, Taguchi J, Brodsky SV, Nakao A, Ogawa Y, Nishijima S, Yokomizo T, Tokunaga K, Fujita T: Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension40 :535– 540,2002
57. Liu Y, Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Rich SS, Bowden DW, Freedman BI: T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the Diabetes Heart Study. J Am Soc Nephrol16 :1085– 1090,2005
58. Mollsten A, Wessman M, Svensson M, Forsblom C, Parkkonen M, Brismar K, Groop PH, Dahlquist G: Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy. Ann Med38 :522– 528,2006
59. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest86 :1343– 1346,1990
60. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: A prospective study. J Am Soc Nephrol12 :541– 549,2001
61. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B: Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: The DCCT/EDIC Genetics Study. Diabetes54 :1238– 1244,2005
62. Ng DP, Tai BC, Koh D, Tan KW, Chia KS: Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia48 :1008– 1016,2005
63. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM: Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. J Am Soc Nephrol9 :1653– 1663,1998
64. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, Parving HH, Cambien F, Tregouet DA, Gut IG, Theva A, Gauguier D, Farrall M, Cox R, Matsuda F, Lathrop M, Hager-Vionnet N: Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: Case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol18 :1284– 1291,2007
65. Ng DP, Placha G, Choo S, Chia KS, Warram JH, Krolewski AS: A disease haplotype for advanced nephropathy in type 2 diabetes at the ACE locus. Diabetes55 :2660– 2663,2006
66. Lee SJ, Choi MG, Kim DS, Kim TW: Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients. Metabolism55 :1– 7,2006
67. Nomiyama T, Tanaka Y, Piao L, Nagasaka K, Sakai K, Ogihara T, Nakajima K, Watada H, Kawamori R: The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet48 :138– 141,2003
68. Mollsten A, Marklund SL, Wessman M, Svensson M, Forsblom C, Parkkonen M, Brismar K, Groop PH, Dahlquist G: A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes56 :265– 269,2007
69. Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS: APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: Results of case-control and family-based studies. Diabetes49 :2190– 2195,2000
70. Hsu CC, Kao KC, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS: Apolipoprotein E and progression of chronic kidney disease. JAMA293 :2892– 2899,2005
71. Mahley RW, Rall SC: Apolipoprotein E: Far more than a lipid transport protein. Ann Rev Genomics Hum Genet1 :507– 537,2000
72. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M: Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis31 :666– 673,1998
73. Roussos L, Ekstrom U, Ehle PN, Oqvist B, Floren CH: Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in Sweden. Scand J Urol Nephrol38 :504– 510,2004
74. Ng MC, Baum L, So WY, Lam VK, Wang Y, Poon E, Tomlinson B, Cheng S, Lindpaintner K, Chan JC: Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3–455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet70 :20– 28,2006
75. Chowdhury TA, Dyer PH, Kumar S, Gibson SP, Rowe BR, Davies SJ, Marshall SM, Morris PJ, Gill GV, Feeney S, Maxwell P, Savage D, Boulton AJ, Todd JA, Dunger D, Barnett AH, Bain SC: Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes47 :278– 280,1998
76. Werle E, Fiehn W, Hasslacher C: Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care21 :994– 998,1998
77. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A: Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet48 :288– 292,1995
78. Ukkola O, Kervinen K, Salmela PI, von DK, Laakso M, Kesaniemi YA: Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis101 :9– 15,1993
79. Vauhkonen I, Niskanen L, Ryynanen M, Voutilainen R, Partanen J, Toyry J, Mercuri M, Rauramaa R, Uusitupa M: Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects. Diabet Med14 :748– 756,1997
80. Onuma T, Laffel LM, Angelico MC, Krolewski AS: Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol7 :1075– 1078,1996
81. Hanson RL, Craig DW, Millis MP, Yeatts KA, Kobes S, Pearson JV, Lee AM, Knowler WC, Nelson RG, Wolford JK: Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes56 :975– 983,2007
